In non-small cell lung cancer demonstrated that pembrolizumab led to a median overall survival of 26.3 months versus 13.4 months with chemotherapy alone in patients with PD-L1 ≥50% (21). The gene discussed is CD274; the disease is non-small cell lung carcinoma.